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Metabolic syndrome (MetS) is a constellation of metabolic de-
rangements that includes insulin resistance, hyperglycemia, 
hypertension, reduced high density lipoprotein cholesterol 
(HDL-C), elevated triglycerides, and abdominal obesity. It was 
originally described by Reaven in 1988 as “syndrome X” or 
“insulin resistance syndrome” [1]. MetS increases the risk for 
development of type 2 diabetes mellitus as well as cardiovas-
cular disease [2]. 
  The prevalence of MetS has increased worldwide, with an 
increase from 19.6% in 1998 to 32.4% in 2009, according to 
the Korean National Health and Nutrition Examination Survey 
(NHANES) [3]. In spite of the increasing prevalence of MetS, 
there are no uniformly accepted diagnostic criteria for MetS. 
Different organizations have suggested their own criteria. The 
National Cholesterol Education Program (NCEP) Adult Treat-
ment Panel-III (ATP III) guidelines [4] are the most widely 
used, and require at least three of the following: 1) central obe-
sity (waist circumference ≥90 cm for Asian men or ≥80 cm 
for Asian women, 2) triglycerides ≥150 mg/dL, or receiving 
drug treatment for high triglycerides, 3) HDL-C <40 mg/dL 
for men or <50 mg/dL for women or receiving drug treatment 
for low HDL-C, 4) systolic/diastolic blood pressure ≥130/85 
mm Hg or receiving drug treatment for high blood pressure, 
and 5) fasting plasma glucose ≥100 mg/dL or receiving drug 
treatment for high fasting plasma glucose levels. However, ac-
cording to the International Diabetes Federation (IDF) criteria 
[5], abdominal obesity (waist circumference ≥90 cm for Asian 
men or ≥80 cm for Asian women) is a prerequisite for the di-
agnosis of MetS, in addition to at least two of the following 
components: 1) triglycerides ≥150 mg/dL or receiving drug 
treatment for high triglycerides, 2) HDL-C <40 mg/dL for men 
or <50 mg/dL for women or receiving drug treatment for low 
HDL-C, 3) systolic/diastolic blood pressure ≥130/85 mm Hg 
or receiving drug treatment for high blood pressure, and 4) 
fasting plasma glucose ≥100 mg/dL or receiving drug treat-
ment for high fasting plasma glucose levels. Yoon et al. [6] 
compared the two criteria. All MetS patients who met the IDF 
criteria also met the revised NCEP criteria. Patients who met 
the NCEP criteria but not the IDF criteria were metabolically 
obese with normal waist circumferences and significantly 
worse metabolic profiles than the MetS-free group. This illus-
trates why the revised NCEP criteria are preferred to the IDF 
criteria for measuring the prevalence of MetS in Korea. 
  Even though the primary mechanism of MetS is insulin re-
sistance, there is still controversy regarding the pathogenesis 
of MetS. Because the clinical features of MetS are shared by 
Cushing’s syndrome (CS), mild hypercortisolism was proposed 
as one of the pathogenic mechanisms of MetS [7]. Shared fea-
tures between MetS and CS are abdominal obesity, high tri-
glycerides, low HDL-C, hypertension, and hyperglycemia. 
  Previous studies have evaluated the association between 
MetS and hypercortisolism by examining fasting plasma corti-
sol, 24-hour urinary free cortisol, cortisol reactivity to some 
stimuli, or profiles of cortisol patterns over the day [8-24]. More 
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recently, salivary cortisol measurements have been used [24]. 
Because lack of circadian rhythmicity is one of the most sensi-
tive indicators of the presence of CS, midnight serum cortisol 
is very helpful as a low dose dexamethasone suppression test, 
but it is impractical for screening outpatients [9]. Midnight 
salivary cortisol, on the other hand, is much more practical for 
screening. Cortisol circulates in the plasma largely bound to 
cortisol binding globulin or albumin. Less than 5% of circulat-
ing cortisol is free cortisol which is a physiologically active 
hormone. Since binding proteins are absent from saliva, the 
concentration of salivary cortisol is in equilibrium with plas-
ma free cortisol [10]. Thus, the salivary cortisol test is a simple, 
reproducible, stress-free, non-invasive and reliable test [11]. 
Interestingly, salivary cortisol testing was first reported about 
30 years ago. There is some variation in cutoff values for sali-
vary cortisol because different commercially available meth-
ods are used, such as radioimmunoassay (RIA), enzyme-
linked immunosorbent assay (ELISA), and tandem mass 
spectrometry (LC-MS) [11].
  Some evidence suggests that circulating cortisol concentra-
tions are higher in patients with MetS compared to healthy 
control subjects. Higher concentrations of urinary free cortisol 
were reported in patients with MetS [12,13]. Increased urinary 
cortisone/cortisol ratios were reported in women with abdom-
inal obesity compared to those with a high proportion of pe-
ripheral fat. Cortisol appears to play a role in abdominal adi-
posity in MetS. Another study [14] did not find any relation-
ship between cortisol and waist circumference, in contrast with 
findings from earlier studies [15,16]. Other studies measured 
the response of hypothalamic-pituitary-adrenal (HPA) axis to 
the various stimuli. Increased response of the HPA axis during 
a low dose adrenocorticotropic hormone test [17] and cortico-
tropin-releasing hormone-vasopressin test [18] is found in 
central obesity. Overall there seems to be a hyperactivity of the 
HPA axis in patients with abdominal obesity. Several reports 
also show an association between higher fasting cortisol levels 
and parameters of MetS such as blood pressure, fasting glu-
cose, and high triglycerides [19-21]. Recently Jang et al. [22] 
reported an association between midnight salivary cortisol 
and MetS. Even though the sample size was small, their data 
supported the hypothesis that cortisol plays an important role 
in the pathogenesis of MetS.
  In contrast, circulating cortisol levels are not always elevat-
ed in obese subjects, and in some studies, they are lower than 
in lean subjects [23-25]. DeSantis et al. [25] analyzed the asso-
ciation between salivary cortisol measured 18 times over 3 days 
and MetS, using data from the Multi-Ethnic Study of Athero-
sclerosis. The area under the curve of cortisol levels was lower 
in the MetS group compared with the control group and there 
was no consistent pattern between MetS components and cor-
tisol levels. This might be partly explained by tissue-specific 
dysregulation of cortisol metabolism, because plasma cortisol 
concentration is determined by the rate of secretion, the rate 
of inactivation, and the rate of excretion of free cortisol.
  11β-hydroxysteroid dehydrogenase (11β-HSD) catalyzes 
the conversion of the hormonally active cortisol to inactive 
cortisone. There are two isoforms of 11β-HSD. 11β-HSD type 
1 (11β-HSD1) converts inactive cortisone to active cortisol in 
key targets such as liver, adipose tissue, gonadal tissue and the 
central nervous system. 11β-HSD2 is expressed in a number 
of tissues and converts cortisol to inactive cortisone. Mutations 
in the 11β-HSD2 gene cause a syndrome of apparent miner-
alocorticoid excess, reflecting insufficient inactivation of corti-
sol in the kidney.
  The expression of 11β-HSD1 appears to be higher in omen-
tal than subcutaneous fat. Treatment with cortisol and insulin 
increased the activity of 11β-HSD1 in adipose stromal cells 
[26], suggesting central obesity may reflect higher 11β-HSD1 
activity. Mice overexpressing 11β-HSD1 in adipocytes develop 
central obesity [27]. Furthermore, 11β-HSD1 knockout mice 
have a reduced risk of obesity and MetS [28]. However, expres-
sion of 11β-HSD1 in adipose tissue is not increased in obese 
humans. The activity of 11β-HSD1 inversely correlates with 
body mass index, but increased proliferation of preadipose tis-
sue as a consequence of decreased 11β-HSD1 expression may 
contribute to increases in visceral adipose tissue in obese hu-
mans [29]. Recent studies showed enhanced expression of the 
11β-HSD1 gene in adipose tissue is associated with obesity, 
insulin resistance, and increased levels of leptin, resistin, and 
cytokines [30]. Therefore, 11β-HSD1 might be a promising 
therapeutic target in obesity and MetS. Carbenoxolone, a non-
selective inhibitor of 11β-HSD1, improves insulin sensitivity 
[31]. Pharmacological inhibition of 11β-HSD1 by metformin, 
rosiglitazone, and clofibrate could explain the beneficial effects 
of these drugs on insulin resistance [32]. Selective and potent 
inhibitors of 11β-HSD1 have been developed [33]. Experimen-
tal studies with 11β-HSD1 inhibitors might support the role of 
11β-HSD1 in the pathogenesis of MetS. 
  In conclusion, MetS is a constellation of metabolic abnor-
malities which predisposes patients to the development of dia-209
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betes, atherosclerosis, and cancer. Because MetS shares clinical 
characteristics of CS, functional hypercortisolism is one of the 
proposed pathogenic mechanisms of MetS. Increased cortisol 
production, hyperreactivity of the HPA axis, and dysregulation 
of 11β-HSD1 seem to contribute to hypercortisolism and MetS. 
Inhibition of cortisol action might be a new therapeutic target 
in patients with MetS. 
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